A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma

M. Reni, R. Berardi, A. Mambrini, L. Pasetto, S. Cereda, V. D. Ferrari, S. Cascinu, M. Cantore, E. Mazza, S. Grisanti

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. Material and methods: A retrospective review of 183 patients submitted to second-line therapy has been performed to identify prognostic factors, provides useful information for patients counseling and generates hypotheses for future studies. Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine- including chemotherapy. Any age, performance status (PS) and chemotherapy regimen were considered. Results: One hundred and eighty-three patients (106 males; 168 metastatic; median age 62 years; median PS 1; 63 submitted to prior curative surgery, 32 to prior radiotherapy) with a median previous progression-free survival (PFS) of 6.7 months were included. Median and 6-month PFS after initiation of salvage therapy were 3.0 months and 20%. Median, 1 and 2 years, overall survival after initiation of salvage therapy were 6.2 months, 17 and 4%, respectively. Previous PFS, CA19.9 levels and age independently predicted OS. Conclusion: Re-challenge with gemcitabine and 5-fluorouracil administration may have a role in selected patients.

Original languageEnglish
Pages (from-to)673-678
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume62
Issue number4
DOIs
Publication statusPublished - Sep 2008

Keywords

  • Chemotherapy
  • Gemcitabine-refractory cancer
  • Pancreatic cancer
  • Second-line therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Fingerprint Dive into the research topics of 'A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this